secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001104659-26-017298
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma: ratutrelvir Phase 2 shows fewer AEs, faster symptom resolution; FDA hold on tivoxavir IND
--------------------------------------------------------------------------------

- Ratutrelvir Phase 2: 10% vs 23.3% adverse events, faster symptom resolution (HR 1.31, p=0.018), no viral rebound vs PAXLOVID.
- Ratutrelvir showed benefit in PAXLOVID-ineligible patients, addressing unmet need in high-risk COVID-19 population.
- Tivoxavir marboxil tablet formulation showed 30% increased pre-clinical exposure, modeled 28-day monthly prophylaxis.
- FDA placed US IND for tivoxavir marboxil on clinical hold due to mutagenicity concerns; formal communication by March 16, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926017298/0001104659-26-017298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926017298/tm266824d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-017298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer